$DXCM

Brown Michael Jon sold $127K of DXCM

Brown Michael Jon (EVP Chief Legal Compliance Off) sold 1,700 shares of DEXCOM INC (DXCM) at $74.42 ($0.13M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brown Michael Jon
Published Jul 16, 2026, 9:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DXCM
Neutral
high confidence
Mentioned
$DXCM
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DXCMNeutralLow
01

Why it matters

The disclosure updates insider ownership records but does not introduce new guidance, trial results, regulatory actions, or deal activity.

02

Market read

Traders may note the insider sale for positioning or sentiment, but it is unlikely to change the fundamental outlook.

03

What to watch

The transaction is explicitly under a pre-arranged 10b5-1 plan, which reduces interpretability versus discretionary selling.

Relevance 3/10Novelty 2/10Timing: Filed after-hours on 2026-07-16, reflecting a sale executed 2026-07-15.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for DexCom.

Company-level read

Ticker impact

$DXCMNeutralHigh confidence
Context

DexCom Form 4 shows EVP Chief Legal Compliance Off Brown sold 1,700 shares at $74.42 on a 10b5-1 plan, totaling $126,514.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is an open-market sale by an insider, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.

Market effects

No meaningful read-across to the medical device or diabetes monitoring sector from a single routine 10b5-1 sale.

None.

None.

Counterpoint

Some traders may still treat insider selling as a weak sentiment signal, especially if multiple recent filings show net selling, but this article alone does not establish that pattern.

Key entities

  • DexCom

    Public company subject of the Form 4 insider transaction disclosure.

  • Michael Jon Brown

    EVP, Chief Legal Compliance Officer who executed the reported sale.

Related articles

$DXCMMed

DexCom (DXCM) Raised Full Year Guidance, Is The Upside Already Priced In?

DexCom (DXCM) reported Q2 2026 results with higher sales and earnings and raised full-year revenue guidance to about $5.18b to $5.25b. The stock has risen sharply recently. Simply Wall St discusses valuation versus a $91.64 fair value estimate and notes reimbursement expansion and CGM coverage, alongside risks from Medicare pricing pressure and competition.

$DXCMHighAI 9/10

DexCom (DXCM) Q2 2026 Earnings Call Transcript

DexCom (DXCM) reported Q2 2026 revenue of $1.31B, up 13% reported and 12% organic year over year. Non-GAAP gross margin was 64.1%, non-GAAP operating income $328.3M, and non-GAAP EPS $0.70. Free cash flow was $600M in H1. FY2026 revenue guidance raised to $5.18B-$5.25B. The company completed the Nutrisense acquisition and discussed CONNECT trial and G7 15-day progress.

$DXCMMed

DexCom Stock Jumps As Q2 Beat Ignites Bullish Re‑Rating

DexCom (NASDAQ: DXCM) shares rose about 11% after a Q2 beat and bullish sentiment around its CGM growth. The company reported Q2 revenue of about $1.31B, up 13% YoY, and adjusted EPS of $0.70 vs $0.61 consensus. The article cites raised 2026 guidance and technical breakout levels near $80 support.

$DXCMMedAI 9/10

DexCom Q2 Earnings Call Highlights

Dexcom (NASDAQ:DXCM) said coverage now extends across four major U.S. PBMs for Type 2 non-insulin patients, targeting 25 million. It is rolling out the G7 15-day system, now available to all adult U.S. G7 customers, and expects Canada in 2H26. CONNECT trial showed a 1.6% A1C improvement vs control. Q2 gross profit was $838.5M (64.1%); net income $269.1M, $0.70/share. Full-year revenue guidance $5.18B-$5.25B.

$DXCMMedAI 8/10

DXCM Q2 Deep Dive: Expanded Access and Product Updates Drive Growth

DexCom reported Q2 revenue of $1.31B vs $1.29B estimates and adjusted EPS of $0.70 vs $0.61, with adjusted EBITDA of $421.3M. It slightly lifted FY guidance to $5.22B. Management cited expanded type 2 diabetes reimbursement, CONNECT trial A1C improvement, and G7 15-day adoption. DexCom also completed the Nutrisense acquisition and is pursuing CMS coverage.